Skip to main content
Erschienen in: Annals of Hematology 4/2015

01.04.2015 | Original Article

Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts

verfasst von: Patricia Font, Javier Loscertales, Carlos Soto, Pilar Ricard, Carolina Muñoz- Novas, Estela Martín-Clavero, Montserrat López-Rubio, Luis Garcia-Alonso, Marta Callejas, Alfredo Bermejo, Celina Benavente, Mónica Ballesteros, Teresa Cedena, María Calbacho, Raquel Urbina, Jesús Villarrubia, Santiago Gil, José María Bellón, José Luis Diez-Martin, Ana Villegas

Erschienen in: Annals of Hematology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Previous studies have shown the reproducibility of the 2008 World Health Organization (WHO) classification in myelodysplastic syndromes (MDS), especially when multilineage dysplasia or excess of blasts are present. However, there are few data regarding the reproducibility of MDS with unilineage dysplasia. The revised International Prognostic Scoring System R-IPSS described two new morphological categories, distinguishing bone marrow (BM) blast cell count between 0–2 % and >2– < 5 %. This distinction is critical for establishing prognosis, but the reproducibility of this threshold is still not demonstrated. The objectives of our study were to explore the reliability of the 2008 WHO classification, regarding unilineage vs. multilineage dysplasia, by reviewing 110 cases previously diagnosed with MDS, and to study whether the threshold of ≤2 % BM blasts is reproducible among different observers. We used the same methodology as in our previous paper [Font et al. (2013) Ann Hematol 92:19–24], by encouraging investigators to include patients with <5 % BM blasts. Samples were collected from 11 hospitals and were evaluated by 11 morphologists. Each observer evaluated 20 samples, and each sample was analyzed independently by two morphologists. Discordance was observed in 36/108 suitable cases (33 %, kappa test 0.503). Diagnosis of MDS with unilineage dysplasia (refractory cytopenia with unilineage dysplasia (RCUD), refractory anemia with ring sideroblasts (RARS) or unclassifiable MDS) was assessed in 33 patients, by either of the two observers. We combined this series with the cases with RCUD or RARS included in our 2013 paper, thus obtaining 50 cases with unilineage dysplasia by at least one of the observers. The whole series showed very low agreement regarding RCUD (5/23, 21 %) and RARS (5/28, 18 %). Regarding BM blast count, the threshold of ≤2 % was not reproducible (discordance rate 32/108 cases, kappa test 0.277). Our study shows that among MDS WHO 2008 categories, interobserver discordance seems to be high in cases with unilineage dysplasia. We also illustrate that the threshold of ≤2 % BM blasts as settled by the R-IPSS may be not easy to reproduce by morphologists in real practice.
Literatur
1.
Zurück zum Zitat Garcia-Manero G (2014) Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89:98–108CrossRef Garcia-Manero G (2014) Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 89:98–108CrossRef
2.
Zurück zum Zitat Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) French–American–British (FAB) Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199CrossRefPubMed Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) French–American–British (FAB) Cooperative Group. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199CrossRefPubMed
3.
Zurück zum Zitat Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, Harris NL (2001) Myelodysplastic syndromes. Introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 63–67 Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman JW, Harris NL (2001) Myelodysplastic syndromes. Introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 63–67
4.
Zurück zum Zitat Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, Vardiman JW, Hellstrom-Lindberg E (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 88–93 Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, Vardiman JW, Hellstrom-Lindberg E (2008) Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL et al (eds) World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 88–93
5.
Zurück zum Zitat Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed
6.
Zurück zum Zitat Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510CrossRefPubMed Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R et al (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510CrossRefPubMed
7.
Zurück zum Zitat Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J et al (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30:820–829CrossRefPubMed Schanz J, Tüchler H, Solé F, Mallo M, Luño E, Cervera J et al (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30:820–829CrossRefPubMed
8.
Zurück zum Zitat Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465CrossRefPubMed Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465CrossRefPubMed
9.
Zurück zum Zitat Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z et al (2011) Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118:4690–4693CrossRefPubMedCentralPubMed Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z et al (2011) Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 118:4690–4693CrossRefPubMedCentralPubMed
10.
Zurück zum Zitat Senent L, Arenillas L, Luño E, Ruiz JC, Sanz G, Florensa L (2013) Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica 98:568–575CrossRefPubMedCentralPubMed Senent L, Arenillas L, Luño E, Ruiz JC, Sanz G, Florensa L (2013) Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica 98:568–575CrossRefPubMedCentralPubMed
11.
Zurück zum Zitat Font P, Loscertales J, Benavente C, Bermejo A, Callejas M, Garcia-Alonso L et al (2013) Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol 92:19–24CrossRefPubMed Font P, Loscertales J, Benavente C, Bermejo A, Callejas M, Garcia-Alonso L et al (2013) Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification. Ann Hematol 92:19–24CrossRefPubMed
12.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMed
13.
Zurück zum Zitat Gonzalez-Porras JR, Cordoba I, Such E, Nomdedeu B, Vallespi T, Carbonell F, Spanish Myelodysplastic Syndrome Registry et al (2011) Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 117:5529–5537CrossRefPubMed Gonzalez-Porras JR, Cordoba I, Such E, Nomdedeu B, Vallespi T, Carbonell F, Spanish Myelodysplastic Syndrome Registry et al (2011) Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer 117:5529–5537CrossRefPubMed
14.
Zurück zum Zitat Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B et al (2013) Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. Leuk Res 37:64–70CrossRefPubMed Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B et al (2013) Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. Leuk Res 37:64–70CrossRefPubMed
15.
Zurück zum Zitat Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C (2000) Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 108:724–728CrossRefPubMed Germing U, Gattermann N, Aivado M, Hildebrandt B, Aul C (2000) Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction. Br J Haematol 108:724–728CrossRefPubMed
16.
Zurück zum Zitat Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24:983–992CrossRefPubMed Germing U, Gattermann N, Strupp C, Aivado M, Aul C (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 24:983–992CrossRefPubMed
17.
Zurück zum Zitat Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B et al (2006) Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91:1596–1604PubMed Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B et al (2006) Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 91:1596–1604PubMed
18.
Zurück zum Zitat Bacher U, Kern W, Alpermann T, Schnittger S, Haferlach C, Haferlach T (2012) Prognosis of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. Leuk Res 36:826–831CrossRefPubMed Bacher U, Kern W, Alpermann T, Schnittger S, Haferlach C, Haferlach T (2012) Prognosis of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course. Leuk Res 36:826–831CrossRefPubMed
19.
Zurück zum Zitat Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496–2506CrossRefPubMedCentralPubMed Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G et al (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364:2496–2506CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Bejar R, Stevenson K, Caughey B, Abdel-Wahab O, Steensma D, Galili N et al (2012) Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 30:3376–3382CrossRefPubMedCentralPubMed Bejar R, Stevenson K, Caughey B, Abdel-Wahab O, Steensma D, Galili N et al (2012) Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 30:3376–3382CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al (2011) Somatic SF3B1 mutation in myelodysplasia with ringed sideroblasts. N Engl J Med 365:1384–1395CrossRefPubMedCentralPubMed Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D et al (2011) Somatic SF3B1 mutation in myelodysplasia with ringed sideroblasts. N Engl J Med 365:1384–1395CrossRefPubMedCentralPubMed
22.
Zurück zum Zitat Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64–69CrossRefPubMed Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478:64–69CrossRefPubMed
23.
Zurück zum Zitat Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP et al (2012) Prognostic irrelevance of ring sideroblast percentage in World Health Organization defined myelodysplastic syndromes without excess blasts. Blood 119:5674–5677CrossRefPubMed Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP et al (2012) Prognostic irrelevance of ring sideroblast percentage in World Health Organization defined myelodysplastic syndromes without excess blasts. Blood 119:5674–5677CrossRefPubMed
24.
Zurück zum Zitat Broséus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E et al (2013) Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 27:1826–1831CrossRefPubMed Broséus J, Alpermann T, Wulfert M, Florensa Brichs L, Jeromin S, Lippert E et al (2013) Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 27:1826–1831CrossRefPubMed
25.
Zurück zum Zitat Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Minamihisamatsu M, Honda S et al (1998) Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 12:482–485CrossRefPubMed Matsuda A, Jinnai I, Yagasaki F, Kusumoto S, Minamihisamatsu M, Honda S et al (1998) Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 12:482–485CrossRefPubMed
26.
27.
Zurück zum Zitat Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R et al (2008) International Working Group on Morphology of Myelodysplastic Syndrome. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93:1712–1717CrossRefPubMed Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R et al (2008) International Working Group on Morphology of Myelodysplastic Syndrome. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica 93:1712–1717CrossRefPubMed
28.
Zurück zum Zitat Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellström-Lindberg E (2004) The WHO classification of MDS does make a difference. Blood 103:3265–3270CrossRefPubMed Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellström-Lindberg E (2004) The WHO classification of MDS does make a difference. Blood 103:3265–3270CrossRefPubMed
29.
Zurück zum Zitat Van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS et al (2013) Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma 54:472–475CrossRefPubMed Van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS et al (2013) Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leuk Lymphoma 54:472–475CrossRefPubMed
Metadaten
Titel
Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts
verfasst von
Patricia Font
Javier Loscertales
Carlos Soto
Pilar Ricard
Carolina Muñoz- Novas
Estela Martín-Clavero
Montserrat López-Rubio
Luis Garcia-Alonso
Marta Callejas
Alfredo Bermejo
Celina Benavente
Mónica Ballesteros
Teresa Cedena
María Calbacho
Raquel Urbina
Jesús Villarrubia
Santiago Gil
José María Bellón
José Luis Diez-Martin
Ana Villegas
Publikationsdatum
01.04.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 4/2015
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2252-4

Weitere Artikel der Ausgabe 4/2015

Annals of Hematology 4/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.